智財技轉處 Department of Intellectual Property and Technology Transfer 智財技轉處 Department of Intellectual Property and Technology Transfer

我們發現一群腺苷類似物，可以同時活化腺苷A2A受體，且抑制大腦中的腺苷轉運子，進而增加蛋白質降解系統的活性，可有效水解突變蛋白，因此降低大腦中突變蛋白質的堆積，進而治療因不正常蛋白質堆積所造成的神經退化疾病。

有效保護神經細胞，延緩神經退化，無明顯副作用。

其中先導藥物最新研發概況：

A Novel First-in-class Huntington’s Disease Drug Candidate

1、Highly unmet medical needs / an orphan drug
2、Patented (first-in-class; dual-function compound)
3、Superior pharmacology / PK profiles
(1) Orally active
(2) Potent and highly efficacious in Huntington disease mouse model (R6/2 mice)
(3) Decent bioavailability (F=65%)
(4) Good compound exposure in target tissues (e.g. brain)
4、Ongoing IND enabling studies
(1) No hERG issues
(2) GLP toxicity / safety pharmacology studies are scheduled
(3) No CMC related issues